 |
62 Diseases |  |
27 Trials |
|
27 Trials |  |
847 News |  |
| «12345678910» |
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
New P3 trial, Combination therapy: Afrezza (clinicaltrials.gov) - Jul 22, 2021
P3, N=264, Not yet recruiting, Sponsor: Mannkind Corporation
- | Tresiba (insulin degludec) / Novo Nordisk
Journal: Relationship between anti-insulin antibody production and severe insulin resistance in a diabetic cat. (Pubmed Central) - Jul 21, 2021
After initiation of prednisolone, the cat was gradually recovered with increasing activity and appetite. Furthermore, satisfactory glycemic control was achieved with combined subcutaneous injection of insulin detemir and insulin degludec.
- | DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
New trial: Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM (clinicaltrials.gov) - Jul 15, 2021
P=N/A, N=40, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
[VIRTUAL] Real-world persistence, adherence, healthcare resource utilisation, and costs in people with type 2 diabetes switching from basal insulin (BI) to 2nd- vs 1st-generation BI (Saint Petersburg Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_1322;
Switching to Gla-300 was associated with significantly better persistence, adherence, and—despite numerically higher pharmacy costs—lower all-cause healthcare resource utilisation versus switching to a 1st-gen BI, in people with T2D previously treated with BI therapy. This is the first study to assess these outcomes in tandem.
- Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
[VIRTUAL] Maternal efficacy, safety, and pregnancy outcomes with degludec vs detemir in the treatment of pregnant women with type 1 diabetes: an international, multicentre, randomised trial (London Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_936;
P3
In pregnant women with T1D, degludec was non-inferior to detemir with respect to HbA1c prior to delivery. Hypoglycaemia rates and pregnancy outcomes were comparable between insulins.
- Tresiba (insulin degludec) / Novo Nordisk
[VIRTUAL] Epidemiology of hypoglycaemic episodes leading to hospitalisations in Denmark over the last two decades (Saint Petersburg Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_642;
Incidence rates of hypoglycaemic episodes leading to hospitalisation are declining in Denmark, and the advent of new treatment alternatives may play a significant role in this decline. From a safety perspective, these findings are important and could be considered by clinicians when assessing treatment options for patients.
- || Tresiba (insulin degludec) / Novo Nordisk
Clinical, Observational data, Review, Journal: Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials. (Pubmed Central) - Jul 9, 2021
These characteristics have provided added therapeutic value for insulin degludec in clinical practice. Thus, the aim of this review is to discuss, within the context of randomized and observational studies, the clinical effects of insulin degludec use in type 1 and type 2 diabetes.
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Levemir out loud! (Twitter) - Jul 8, 2021
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk, Byetta (exenatide) / AstraZeneca
Clinical, Review, Journal: Using RWE research to extend clinical trials in diabetes: An example with implications for the future. (Pubmed Central) - Jun 26, 2021
Thus, the aim of this review is to discuss, within the context of randomized and observational studies, the clinical effects of insulin degludec use in type 1 and type 2 diabetes. Despite numerous challenges, RWE can be used to complement evidence from RCTs.
- || Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Clinical, Journal: A pragmatic randomized clinical trial of insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of ACHIEVE Control. (Pubmed Central) - Jun 26, 2021
P4
The ACHIEVE Control study results add value to treatment decisions and options for patients, healthcare providers, payers, and decision makers. ClinicalTrials.
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal: Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study. (Pubmed Central) - Jun 22, 2021
Compared with NPH, IDet could control blood glucose and reached the targets faster and more effectively, thus reducing the number of insulin injections and the incidence of hypoglycemia in pregnant women without increasing adverse birth outcomes. Therefore, for pregnant women with gestational diabetes, who require insulin therapy, IDet would be an ideal basal insulin being worthy of promotion in clinical settings.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Levemir adlı ilacın firma tarafından iskontosunun uygulanmamasından dolayı ne kadar hasta ilacını alamıyor ya da değiştiriyor ya da az adette alıp ihtiyacından az ünitede kullanıyor biliyor musunuz? Ve bundan dolayı yaptığınız zararı yapmadığınız iskonto karşılar mı @novonordisk (Twitter) - Jun 19, 2021
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal: Comparison of the Efficacy and Safety of Insulin Detemir Administered Once Daily According to Two Titration Algorithms (3-0-3 and 2-4-6-8) in Patients with Type 2 Diabetes Mellitus. (Pubmed Central) - Jun 16, 2021
A trend towards fewer hypoglycaemia episodes after dose stabilisation was seen with the simpler G3. Clinically, this may be an important observation, as a simpler titration algorithm may support self-management and maintenance of insulin therapy.
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal: Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT). (Pubmed Central) - Jun 5, 2021
This post hoc analysis of the ORBIT registry provides key information on the 6-month dose of BI needed for effective glycemic control in Chinese T2DM patients. Furthermore, it identified crucial patient characteristics that are significant determinants of the dose of BI in a real-world setting.
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
[VIRTUAL] Basal Insulin Management in Inpatients Who Are Not Eating: Is There a Difference between Medical and Surgical Patients? () - May 29, 2021 - Abstract #ADA2021ADA_1237;
A numerically higher incidence of hyperglycemia was observed in patients receiving 100% insulin detemir in both medicine and surgery patients. Further education is planned to reduce hyperglycemia.
- Tresiba (insulin degludec) / Novo Nordisk
[VIRTUAL] Effects of Insulin Degludec in Patients with Diabetes Using Continuous Glucose Monitoring: A Scoping Review () - May 29, 2021 - Abstract #ADA2021ADA_1116;
The studies compared Deg with insulin glargine 100U/mL (n=130), insulin glargine 300U/mL (n=100), or insulin detemir (n=32). Deg leads to similarly effective, stable and safe glycemic control with comparable insulin dose requirement to other basal insulin on the current evidence.
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal: Glycemic Variability With Insulin Glargine Versus Detemir in Hospitalized Patients With Diabetes. (Pubmed Central) - May 20, 2021
Insulin detemir exhibited less GV than insulin glargine, although the small difference is unlikely to be clinically significant. Application of this data will aid in formulary decisions and support the use of either agent within the hospital setting.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Stability of Insulin Detemir Injection in Different Primary Packaging Systems at Room Temperature. (Pubmed Central) - May 15, 2021
Stability studies in different packaging systems demonstrated that insulin detemir remained stable for at least 7 days in a closed glass vial or glass syringe, but for only 3 days in a plastic syringe at RT. This study will allow pharmacists in the hospital setting to deliver patient-specific insulin doses into an insulin syringe with confidence in the stability.
- | Tresiba (insulin degludec) / Novo Nordisk
Journal: Development and validation of a method for quantification of human insulin and its synthetic analogues in plasma and post-mortem sera by LC-MS/HRMS. (Pubmed Central) - May 15, 2021
At the LOQ level, for all insulins and all samples, accuracy was between 70 and 130% and precision inferior to 30%. The validated method was applied to five subjects participating in therapeutic monitoring of insulin and to seven post-mortem cases.
- ||| Bydureon (exenatide XR once-weekly) / AstraZeneca, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical: I had a patient recently that my physician wanted to start on Levemir who was on Bydureon with persistent nausea 😭😭 It’s still his go to (Twitter) - May 13, 2021
- || Tresiba (insulin degludec) / Novo Nordisk
Review, Journal: (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus. (Pubmed Central) - Apr 22, 2021
Data on patient-important outcomes such as QoL, macrovascular and microvascular diabetic complications were sparse or missing. No clinically relevant differences were found between children and adults.
- ||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal, Adverse events: Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System. (Pubmed Central) - Apr 15, 2021
No clinically relevant differences were found between children and adults. When we compared the proportionality of hypoglycemic events among the total number of reported AEs for each of the two basal insulins through disproportionality analysis using the spontaneous ADR reporting system, IDeg showed a relatively lower rate of reported hypoglycemic events than IDet.
- Myalept (metreleptin) / Novelion
[VIRTUAL] Metreleptin and Metformin Use in an Infant With Congenital Generalized Lipodystrophy Secondary to AGPAT2 Mutation () - Mar 27, 2021 - Abstract #ENDO2021ENDO_3363;
For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date: Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - Mar 24, 2021
P4, N=260, Recruiting, Sponsor: Emory University
The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021. Trial completion date: Aug 2022 --> Dec 2024 | Trial primary completion date: Aug 2022 --> Sep 2024
- Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi
[VIRTUAL] Consequences of switching from twice daily administered basal insulin to once daily insulin glargine 300 U / ml (Gla-300) in patients with type 1 diabetes: the phase 4 study OPTIMIZE (Channel 1) - Mar 21, 2021 - Abstract #DDG2021DDG_432;
P4
Before participating in the study, 45.7% insulin glargine received 100 U / ml and 52.1% insulin detemir... In this clinically challenging population, switching from twice daily basal insulin to once daily Gla-300 plus mealtime insulin resulted in greater overall therapy satisfaction and an improvement in HbA1c without increasing the rate of hypoglycaemia.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK. (Pubmed Central) - Mar 16, 2021
In this clinically challenging population, switching from twice daily basal insulin to once daily Gla-300 plus mealtime insulin resulted in greater overall therapy satisfaction and an improvement in HbA1c without increasing the rate of hypoglycaemia. In this real-world observational study, there was an association between all-cause mortality and basal insulin choice in insulin-naïve people with T2D; the mortality risk was lower with detemir versus glargine after adjustment for potential confounders.
- | Tresiba (insulin degludec) / Novo Nordisk
Journal: Relationship between anti-insulin antibody production and severe insulin resistance in a diabetic cat. (Pubmed Central) - Mar 9, 2021
After initiation of prednisolone, the cat was gradually recovered with increasing activity and appetite. Furthermore, satisfactory glycemic control was achieved with combined subcutaneous injection of insulin detemir and insulin degludec.
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Review, Journal: A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes. (Pubmed Central) - Feb 26, 2021
Despite these limitations, point estimates of HbA1c were used to rank the insulins and formed the basis of NG17 guidance. This study queries whether such analyses should be used to make specific clinical recommendations.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Metabolite Identification of Therapeutic Peptides and Proteins by Top-down Differential Mass Spectrometry and Metabolite Database Matching. (Pubmed Central) - Feb 13, 2021
Using insulin detemir as an example, we demonstrated that top-down differential mass spectrometry (dMS) was able to distinguish and discover metabolites from complex biological matrices...Finally, the MS/MS sequence tags enabled unambiguous characterization of metabolite structures when isobaric/isomeric candidates were present. This platform is widely applicable to TPPs with complex structures and will ultimately guide the structural optimization of TPPs in pharmaceutical development.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Exploration of temperature and shelf-life dependency of the therapeutically available Insulin Detemir. (Pubmed Central) - Feb 7, 2021
This platform is widely applicable to TPPs with complex structures and will ultimately guide the structural optimization of TPPs in pharmaceutical development. These findings are critical to our understanding of the behaviour of this particular clinically relevant drug, as it will allow the development of future generations of peptide-based therapies with greater clinical efficacy.
- Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Case Series: Exacerbation of Insulin Resistance With Active COVID 19 Infection (On-Demand) - Feb 2, 2021 - Abstract #ENDO2021ENDO_1102;
Cconsideration should be given to assessing therapeutic interventions to enhance insulin sensitivity and improve outcomes. Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20.
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
[VIRTUAL] Excellent Maternal and Fetal Outcomes Associated With Early Detection and Treatment of Cushing’s Syndrome During Pregnancy (On-Demand) - Feb 2, 2021 - Abstract #ENDO2021ENDO_723;
CS in pregnancy is associated with high maternal and fetal morbidity and mortality, thus early diagnosis and prompt treatment is essential. Our case demonstrates the importance of discussing contraception with Cushing's patients of reproductive age.
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal: Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks. (Pubmed Central) - Jan 22, 2021
Our case demonstrates the importance of discussing contraception with Cushing's patients of reproductive age. Compared with IGlar, in T2DM patients after ACS or AIS, IDet was not associated with increased risks of CV death, nonfatal MI, or nonfatal stroke.
- || Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
Clinical, Review, Journal: Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel. (Pubmed Central) - Dec 29, 2020
Therefore, for more effective and accurate diabetes management, the development of an integrated approach with second-generation basal insulin and glucometrics involving GV and TIR is the need of the hour. With this objective, a multinational group of endocrinologists and diabetologists reviewed the existing recommendations on TIR, provided their clinical insights into the individualization of TIR targets, and elucidated on the role of the second-generation basal insulin analogues in addressing TIR.
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] A Quality Improvement Project at a Community Based Hospital Utilizing a Basal-Bolus Protocol for Optimization of Blood Glucose Control () - Dec 26, 2020 - Abstract #ASHP2020ASHP_4327;
If the collaborative practice agreement is approved, it will then be presented to the Local Medical Executive Committee to be approved for pharmacy dosing. Following initiation of the basal-bolus protocol, data will be collected and compared to pre-implementation data to evaluate effectiveness.
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
[VIRTUAL] Appropriate management of long-acting insulin for hospitalized patients who are unable to eat () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3638;
Following initiation of the basal-bolus protocol, data will be collected and compared to pre-implementation data to evaluate effectiveness. The primary endpoint will be incidence of hypoglycemia (180 mg/dL) after NPO status and insulin detemir dose adjustment during hospital admission.
- Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
[VIRTUAL] Clinical controversies in gestational and pre-gestational diabetes: a cross-sectional survey () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3127;
There is controversy around when to check post-prandial glucose in pregnancy and use of aspirin. Limitations include the small sample size.
- Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
[VIRTUAL] Impact of conversion from home insulin glargine to inpatient insulin detemir on rates of hypoglycemia () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1067;
Patients that had a 1:1 unit dose interchange from home U300 insulin glargine to insulin detemir were found to be associated with higher rates of hypoglycemia, faster onset of hypoglycemia, and required less inpatient doses of insulin to create a hypoglycemic event than a 1:1 dose interchange from U100 insulin glargine. While not explicitly determined in this study, a dose reduction from U300 insulin glargine should be considered when converting to insulin detemir in an inpatient setting.
- || Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
Clinical, Review, Journal: (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. (Pubmed Central) - Dec 22, 2020
Additionally, low-certainty evidence and trial designs that did not conform with current clinical practice meant it remains unclear if the same effects will be observed in daily clinical practice. Most trials did not report patient-relevant outcomes.
- ||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion, Combination therapy: EXPECT: Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes (clinicaltrials.gov) - Dec 21, 2020
P3, N=225, Completed, Sponsor: Novo Nordisk A/S
Most trials did not report patient-relevant outcomes. Active, not recruiting --> Completed
- || Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
Review, Journal: Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel. (Pubmed Central) - Dec 17, 2020
Practical and easily implementable tips for patients and involvement of stakeholders (caregivers and healthcare providers) to facilitate insulin acceptance were also outlined by the expert panel. Simplified and convenient insulin regimens like basal insulin analogues are advised during and following the pandemic in order to achieve glycemic control in people with uncontrolled T2DM.
- || Lantus (insulin glargine) / Sanofi
Clinical, Journal: Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins. (Pubmed Central) - Dec 17, 2020
Simplified and convenient insulin regimens like basal insulin analogues are advised during and following the pandemic in order to achieve glycemic control in people with uncontrolled T2DM. Overall, glargine use was not associated with an increased risk of breast cancer compared with NPH or detemir in female Medicare beneficiaries.
- | Tresiba (insulin degludec) / Novo Nordisk
Journal: Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France. (Pubmed Central) - Nov 22, 2020
New basal insulins are expected to be integrated into clinical practice. This analysis shows that their use does not impact upon the management cost of insulin therapy in people with T2DM.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Investigations of albumin-insulin detemir complexes using molecular dynamics simulations and free energy calculations. (Pubmed Central) - Nov 19, 2020
The binding to FA4 is further supported by DLS competition experiments with the prototypical FA4 ligand, ibuprofen, showing displacement of detemir by ibuprofen. This study provides information on albumin-detemir binding on a molecular level, which could be utilized in a rational design of future lipidated albumin-binding peptides.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion, Enrollment change, HEOR: Determin: Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy (clinicaltrials.gov) - Nov 5, 2020
P4, N=108, Completed, Sponsor: The University of Texas Health Science Center, Houston
This study provides information on albumin-detemir binding on a molecular level, which could be utilized in a rational design of future lipidated albumin-binding peptides. Active, not recruiting --> Completed | N=216 --> 108
- [VIRTUAL] Utilization of Glucose-Lowering Medications Among US Medicare Beneficiaries with CKD Between 2007 and 2016 (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1814;
Use of metformin and newer glucose-lowering medication classes is increasing in CKD patients with type 2 diabetes. We anticipate that percentages of CKD patients using these newer agents will increase.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
How many mLs of Levemir can you buy for those 99$? (Twitter) - Oct 9, 2020
- ||| Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
If you fulfil the criteria of "HbA1c is still 8.5% or above despite carefully trying to manage your diabetes, including the use of Lantus or Levemir" - could your DSN decline referring you to to the insulin pump team as your Libre graph in the past two weeks looks great? (Twitter) - Oct 2, 2020
- || Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi
Clinical, Journal, Real-World Evidence: Switching to insulin glargine 300 units/mL in real-world older type 2 diabetes patients (DELIVER 3). (Pubmed Central) - Sep 30, 2020
We anticipate that percentages of CKD patients using these newer agents will increase. Among older adults with T2D, switching to Gla-300 vs Gla-100/IDet was associated with greater/similar improvements in glycaemic control, and generally less hypoglycaemia.
- Lantus (insulin glargine) / Sanofi
[VIRTUAL] Glycogenic Hepatopathy in the Setting of Diabetic Ketoacidosis (DKA) () - Sep 15, 2020 - Abstract #ACG2020ACG_2756;
During the workup of GH, it is crucial to include non-alcoholic fatty liver disease (NAFLD) on the differential due to the potential for cirrhosis in NAFLD. Further research on GH is advised particularly on the development of fibrosis and for an ideal noninvasive diagnostic test.